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The Leu33Pro polymorphism of the gene encoding β3 integrin (ITGB3) is associated with acute 
coronary syndromes and inﬂuences platelet aggregation. Three common promoter polymorphisms 
have also been identified. The aims of this study were to (1) investigate the influence of the ITGB3 
−400C/A, −425A/C and −468G/A promoter polymorphisms on reporter gene expression and nuclear 
protein binding and (2) determine genotype and haplotype associations with platelet αIIbβ3 receptor 
density. Promoter haplotypes were introduced into an ITGB3 promoter-pGL3 construct by site 
directed mutagenesis and luciferase reporter gene expression analyzed in HEL and HMEC-1 cells. 
Binding of nuclear proteins was assessed by electrophoretic mobility shift assay. The association of 
ITGB3 haplotype with platelet αIIbβ3 receptor density was determined in 223 subjects. Species 
conserved motifs were identified in the ITGB3 promoter in the vicinity of the three polymorphisms. 
The GAA, GCC, AAC, AAA and ACC constructs induced ∼ 50% increased luciferase expression relative 
to the GAC construct in both cell types. Haplotype analysis including Leu33Pro indicated ﬁve common 
haplotypes; no associations between ITGB3 haplotypes and receptor density were found. However, 
the GCC-Pro33 haplotype was associated with significantly higher vWF activity (128.6 [112.1–145.1] 
%) compared with all other haplotypes (107.1 [101.2–113.0] %, p = 0.02). In conclusion, the GCC-
Pro33 haplotype was associated with increased vWF activity but not with platelet αIIbβ3 receptor 
density, which may indicate ITGB3 haplotype influences endothelial function. 
 
 
1. Introduction  
Receptor-mediated interactions between leukocytes, endothelial cells and platelets and 
coagulation factors and extracellular matrix proteins at the sites of vascular injury are central to 
the pathogenesis of atherosclerosis and thrombosis [1]. β3 integrin is a component of the platelet-
specific αIIbβ3 receptor and the more widely distributed αv β3  receptor. Platelets play a key role in 
arterial thrombosis and the αIIbβ3 receptor is central to these processes as the mediator of platelet 
aggregation at the site of vascular injury. The αv β3   receptor is variably expressed by a number of 
cell types including endothelial cells and vascular smooth muscle cells [2]. Increased endothelial 
cell and vascular smooth muscle cell expression of αv β3   in coronary artery atherosclerotic 
plaques have been reported [3]. Consequently variants of the gene encoding β3 integrin (ITGB3) 
may influence the development of cardiovascular disease through modification of the function of 
αIIbβ3 and αv β3.  
    
 
Several polymorphisms in the ITGB3 gene have been identified including the Leu33Pro (PlA) variant 
and the −400C/A, −425A/C and −468G/A promoter polymorphisms [4]. Studies have demonstrated 
associations between the Pro33 allele (PlA2) and premature myocardial infarction (MI), ischemic 
stroke and restensosis following coronary angioplasty [5, 6]. Pro33 is associated with a lower 
threshold for αIIbβ3 activation in response to ADP, and enhanced α-granule release, clot retraction 
and adhesion to fibrinogen [7, 8]. Limited information is available regarding the functional effects of 
the −400C/A, −425A/C and −468G/A promoter polymorphisms. The aims of this study were to (I) 
investigate the influence of the −400C/A, −425A/C and −468G/A promoter gene polymorphisms on 
reporter expression and nuclear protein binding and (ii) determine genotype and haplotype
associations with platelet αIIbβ3 receptor density.  
2. Materials and methods  
2.1. Bioinformatics  
Bioinformatics analyses were carried out to compare the 5’ region of the human (accession number 
AY706100), chimp (AY413572), mouse (AY413573) and chicken (X75348) ITGB3 genes to determine 
regions of conservation. The first 500 bp 5’ to the ATG of each species were analyzed by FootPrinter 
against the default phylogenetic tree to indicate potential regulatory elements [9]. The software 
produced short regions of sequences (up to 10 bp in length) that were highly conserved (maximum 
of 2 bp difference) between species.  
2.2. Generation of variant ITGB3 reporter constructs  
The ITGB3 promoter region was cut from a previously reported ITGB3-pGL2 vector [10] and 
ligated into pGL3 by digestion with ﬁve units of KpnI and NheI, and ligation with T4 ligase. The wild 
type ITGB3 5’ region construct will be referred to as ITGB3-pGL3-GAC in relation to the more 
common alleles located at positions −468, −425 and −400. Haplotypes were introduced into the 
ITGB3pGL3-GAC construct by site directed mutagenesis using the GeneEditorTM
 
in vitro Site 
Directed Mutagenesis system (Promega). Mutagenic oligonucleotides were designed with the 
relevant mismatch in the middle:  




The −400A and −468A variants were introduced using the manufacturer’s standard protocol. A 
modified protocol was utilized to generate the −425C variant; the mutagenic oligonucleotide was 
added at the alkaline denaturation stage, and the initial temperature for oligonucleotide annealing 
was increased to 83°C. Twenty colonies were picked for each mutagenesis reaction and successful 
mutagenesis confirmed by genotyping and sequencing. The sequence of the ITGB3 promoter (from 







2.3. Cell culture and transient transfections  
Human erythroleukemic (HEL 92.1.7) cells (αIIbβ3  expressing, representative of megakaryocytic 
cells) were grown in RPMI 1640 medium (Sigma), supplemented with 10% foetal calf serum (FCS) 
(First Link Ltd.), 2 mM glutamine and antibiotic mix (10,000 U penicillin, 10 mg streptomycin and 
25 μg amphotericin B per ml). Cells were transiently co-transfected by electroporation with the 
ITGB3pGL3 constructs and Renilla Luciferase-CMV (pRL-CMV) vector (Promega), as the internal 
control, at a ratio of 50:1. For transfection, 1 × 10
7 
cells per sample were pelleted and resuspended 
in 0.8 ml PBS, 10 μg of DNA was added and cells were electroporated at 500 μF, 0.4 kV (BioRad 
Gene Pulser). The electroporated cells were seeded in 25 ml of pre-warmed media and incubated at 
37 °C and 5% CO2 for 48 h prior to reporter gene analysis. 
 
Human Microvascular Endothelial cells (HMEC-1, αVβ3 expressing, representative of endothelial 
cells) were grown in MCDB 131 media (Invitrogen), supplemented with 10% FCS, antibiotic mix, 2 
mM glutamine, 0.001% epidermal growth factor and 1 μg/ml hydrocortisone. HMEC-1 cells were 
transiently transfected with Lipofectin (Invitrogen): 5 × 10
5 
cells were plated on 60 mm plates 24 h 
prior to transfection with 3 μg DNA (100:1 ratio of ITGB3-pGL3 constructs to pRL-CMV) and 20 ml 
Lipofectin, according to manufacturer’s instructions, followed by incubation at 37°C and 5% CO2 for 
24 h prior to reporter gene analysis. 
 
2.4. Luciferase reporter gene expression analysis  
Luciferase reporter gene analysis was carried out using the Dual-Luciferase Reporter Assay system 
(Promega). Transfected HEL cells were pelleted by centrifugation, washed, and 1 × 10
7 
cells lysed 
with 250 μl passive lysis buffer (PLB). Transfected HMEC-1 cells were washed, and lysed with 1 ml 
PLB. Renilla and ﬁreﬂy luciferase activities were determined in 20 ml of centrifuged cell lysate 
according to manufacturer’s instructions using a PHL luminometer (Mediators). Fireﬂy luciferase 
values were normalized to Renilla luciferase activity. Eight independent sets of transfections were 
carried out, and results are expressed as the activity of each construct relative to the ITGB3-pGL3-
GAC construct.  
2.5. Electrophoretic mobility shift assay (EMSA)  
Nuclear proteins were extracted from 5 × 106 HEL and HMEC-1 cells according to the method 
described by Andrews and Faller [11]. Fluorescein-labelled sense oligonucleotides were synthesized 
with the polymorphic variant in the centre, as follows:  
       -468G/A: forward 5’-AGAGAAGGCATTCA
G
/ACAGATGTTTGCCAG-3’ 


























Sense and antisense oligonucleotides were annealed and gel purified, and 1.5 pmol  
used in each binding reaction. EMSA reactions were performed in binding buffer  
(20% glycerol, 20 mM Tris, pH 7.5, 100 mM KCl, 1 mM DTT) with 0.1 μg/μl poly dI/dC and 
35 μg of nuclear protein extract. For competition assays, 1-, 10-and 50-fold molar excess of 
unlabelled specific or non-specific competitor (SP1: forward 5’-ATTCGATCGGGGCGGGGCGAGC-3’
and reverse 5’-GCTCGCCCCGCCCCGATCGAA-3’) were added. Reaction mixes were incubated at RT 
for 30 min and then electrophoresed on an 8% polyacrylamide gel with 5% stacking gel in 0.25× TBE 
(22.5 mM Tris-borate and 0.5 mM EDTA, pH 8.3) at 200V for 6h at 15°C. The gel was visualized 
using a FX Molecular Imager (BioRad).
2.6. Genotyping of ITGB3 polymorphisms   
    The −468G/A polymorphism were genotyped using an Assays-by-DesignSM
 
SNP genotyping assay 
(Applied Biosystems):  
forward primer 5’ -GGCAAGAAAAAAATTAGTGAATAATAAAGGACTGA-3’ 




Probes were labeled with VICTM
 
for detecting the −468G allele and 6-FAMTM
 
for detecting the −468A 
allele, and following PCR amplification, fluorescence detection was carried out using an ABI PRISM 
7700 SDS (Applied Biosystems). The −425A/C polymorphism was genotyped by PCR-RFLP with 
primers: forward 5’-CGAGGCTCTTCATGGACCTA3’ and reverse 5’-CACATTCACCCACTACCTCGAAT-3’ 
and digestion with ApoI (the underlined base is a mismatch to introduce an ApoI site in the presence 






with RsaI. The Leu33Pro polymorphism was genotyped as previously described [12].  
2.7. Subject recruitment and analysis of αIIbβ3 receptor expression  
Subjects (n = 233) were recruited by the Baylor College of Medicine Thrombosis Research Group 
for analysis of the relationship between ITGB3 polymorphisms and αIIbβ3 receptor expression. The 
study population comprised healthy subjects, recruited through local advertising, who were free from 
a history of cardiovascular disease and were not taking aspirin (n = 138), as previously described 
[13] and subjects who had previously (>3 months) undergone coronary artery bypass surgery 
(CABG, n = 85) who were taking aspirin. All subjects gave informed consent according to a protocol 
approved by the Baylor College of Medicine institutional review board. Platelet αIIbβ3 receptor 
expression was measured by flow cytometry using phycoerythrin-conjugated monoclonal antibody 
HIP8 (anti-CD41a; BD-Pharmingen) and expressed as mean fluorescent intensity, as previously 
described [14]. Fibrinogen concentration was determined by the Clauss method and vWF activity was 
determined using a ristocetin cofactor assay, as previously described [14].  
2.8. Statistical analysis  
Non-normally distributed variables were log-transformed to enable parametric analyses. 
Comparisons between two groups of continuous variables were carried out using Student’s 
independent t-test and more than two groups by ANOVA. Data are presented as mean (geometric 
mean) with either S.D. (antilog S.D.) or 95% confidence intervals (CI). Age did not conform to 
normal distribution and is presented as median with 25th and 75th percentiles in descriptive 
statistics. Differences between categorical variables were ascertained using Chi-square analysis. All 




3.1. Bioinformatics analysis of the ITGB3 promoter  
FootPrinter analysis (Fig. 1) indicated conserved motifs in the ITGB3 5’ region located in the region 
up to 500 bp from the ATG codon. The −400C/A polymorphism is within a motif conserved between 
human and chimp (TGTGTCCCAA) and the −425A/C and −468G/A polymorphisms are between 
conserved motifs. The evolutionary conservation of regions within the 5’
 
gene regulatory region 
indicated that these sequences might be functionally relevant. To determine if the promoter 
polymorphisms were functional, the luciferase reporter gene system was utilized together with 
analysis of nuclear protein binding.  
3.2. Influence of ITGB3 −468/−425/−400 haplotypes on luciferase reporter gene expression and 
nuclear protein binding profile  
Luciferase reporter gene analyses indicated significant differences in reporter gene expression 
according to ITGB3 promoter haplotype in both HEL (p = 0.035) and HMEC-1 cells (p = 0.048), as 
shown in Fig. 2. Similar luciferase expression patterns were obtained from the HEL and HMEC-1 cells. 
The GAA, GCC, AAC, AAA and ACC constructs induced ∼ 50% increased luciferase expression relative 
to the GAC construct whereas the GCA and ACA constructs showed similar expression to GAC in both 
cell types. These results indicated that the three polymorphisms in the ITGB3 promoter may be 
functional and lead to a difference in nuclear protein binding. Each polymorphic variant was, 
therefore, analyzed for differences in nuclear protein binding with HEL and HMEC-1 nuclear protein 
extracts. No difference in the nuclear protein binding proﬁle was observed for the −400C/A, −425A/C 
and −468G/A allelic variants (data not shown).  
 
3.3. Association of ITGB3 polymorphisms and haplotype with platelet αIIbβ3 receptor density  
The relationship between ITGB3 polymorphisms and αIIbβ3 receptor density was investigated in 223 
subjects. The characteristics of the study population, including ethnicity, are presented in Table 1. 
The mean receptor density (expressed as mean ﬂuorescence intensity, MFI) was 136 (range: 81–
192). There was no significant difference in mean receptor density between the different ethnic 
groups studied (Caucasian: 137 [S.D. 18]; African American: 134 [S.D. 19]; Mexican American: 135 
[S.D. 16]; Asian: 143 [S.D. 27]; other: 131 [S.D. 22], p = 0.59). αIIbβ3 receptor density was 
significantly inversely correlated with BMI (r = −0.264, p < 0.001) and ﬁbrinogen (r = −0.155, p = 
0.02) but there was no correlation between αIIbβ3 receptor density and vWF activity (r = −0.019, p = 
0.78). There was no signiﬁcant correlation between receptor density and age (r = −0.096, p = 0.16) 
and no significant difference in αIIbβ3 receptor density between men and women, or between smokers 
and non-smokers (data not shown). There was no significant difference in receptor density between 
CABG patients taking aspirin and healthy subjects not taking aspirin, nor was there a significant 








The genotype distributions of the −400C/A, −425A/C, −468G/A and Leu33Pro polymorphisms 
conformed to Hardy Weinberg equilibrium. The −400C/A polymorphism was in significant linkage 
disequilibrium with the −425A/C (D’
 
= −1.0, p = 0.006) and −468G/A polymorphisms (D’
 
= 0.93, p 
< 0.0001) but not with the Leu33Pro polymorphism. The −425A/C polymorphism was in significant 
linkage disequilibrium with the −468G/A (D’
 
= −0.66, p = 0.04) and the Leu33Pro (D’
 
= 0.67, p < 
0.0001) polymorphisms. There was no significant linkage disequilibrium between the −468G/A and 
Leu33Pro polymorphisms. Six promoter haplotypes were identiﬁed, as shown in Table 2 (denoted A–
F), with the four most frequent haplotypes accounting for 98% of the 446 chromosomes analyzed. 
Inclusion of the Leu33Pro polymorphism in haplotype analysis gave rise to 11 different haplotypes, as 
shown in Table 2 (denoted 1–11), with the five most common haplotypes accounting for 94% of the 
446 chromosomes analyzed.  
Analysis of the relationship of individual SNPs with receptor density did not indicate any association 
of genotype with receptor density, as shown in Table 3. The relationship of receptor density with 
promoter haplotype and haplotype including Leu33Pro was also analysed; there was no significant 
difference in receptor density according to ITGB3 haplotypes (data not shown).  
 
3.4. Association of ITGB3 polymorphisms and haplotype with plasma ﬁbrinogen and vWF activity  
There was no significant difference in fibrinogen according to ITGB3 genotype, as shown in Table 
3, or haplotype (data not shown). There was no significant association of the −400C/A and −468G/A 
polymorphisms with vWF activity, however, there was a signiﬁcant association of the −425A/C 
polymorphism and a borderline association of Leu33Pro with vWF activity, as shown in Table 3. 
Analysis of the relationship of promoter haplotypes and haplotypes including Leu33Pro with vWF 
activity did not indicate any signiﬁcant associations (data not shown), however, the data was 
suggestive of potential differences in vWF activity, particularly in haplotype combinations including 
haplotype 3 (GCC-Pro33). To investigate this further we created a dummy variable including all 
subjects with haplotype combinations including haplotype 3 (n = 43) compared with subjects 
homozygous for haplotype 1 (GAC-Leu33) and compared vWF activity: vWF was significantly higher 
in subjects possessing haplotype 3 (128.6 [112.1, 145.1]%) compared to subjects homozygous for 
haplotype 1 (106.3 [98.1, 114.5] %, p = 0.02). vWF was also significantly higher in subjects 
possessing haplotype 3 when compared with all other subjects (107.1 [101.2, 113.0]%, p = 0.02).  
 
vWF activity differed significantly by ethnicity, with African American subjects having significantly 
lower vWF (96.6 [S.D. 37.8] %) than Caucasian subjects (120.4 (S.D. 44.1) %, p = 0.02 after Sheffe 
post hoc analysis). Furthermore, although ITGB3 haplotype did not differ significantly by ethnicity, 
haplotype 3 was less prevalent in African Americans (10.4%) than Caucasians (21.4%, p = 0.08). 
Therefore we analysed the relationship of haplotype 3 with vWF activity accounting for ethnicity and 




 4. Discussion  
Regions of a gene that are conserved between species are likely to be functionally significant 
and bioinformatics analysis of the region of ITGB3 promoter containing the −400C/A, −425A/C and 
−468G/A polymorphisms indicated a number of regions conserved between species, suggesting 
they may be important in regulation of ITGB3 expression. Luciferase reporter gene analyses in 
cells representative of megakaryocyte and endothelial cells indicated modest (~50%) increases in 
reporter gene expression for the GAA, GCC, AAC, AAA and ACC constructs relative to the GAC 
construct, supporting a potential role for the polymorphisms in modulating gene expression. In 
contrast, EMSA analyses did not indicate any clear difference in nuclear protein binding pattern 
between the alleles of each polymorphism. However, luciferase reporter gene and EMSA analyses 
do not take into account the native chromatin structure of the human ITGB3 gene and therefore 
the inconsistency of results between the two methods does not in itself negate an effect of the 
polymorphisms on ITGB3 expression in vivo. Therefore, to determine whether the differences in 
reporter gene expression translated into differences in αIIbβ3 expression in platelets, genotype and 
haplotype associations with receptor expression were determined.     
The extent of linkage disequilibrium between the promoter polymorphisms and the Leu33Pro 
polymorphism were similar to those reported by O’Halloran et al. [15]. Six of the eight potential 
promoter haplotypes were identified in the present study and inclusion of the Leu33Pro 
polymorphism resulted in the detection of 11 haploytpes, in keeping with those of O’Halloran et al. 
[15]. The prevalence of the three most common haplotypes (GAC-Leu33, AAA-Leu33, GCC-Pro33) 
were approximately equivalent in the two study groups, with the majority of Pro33 alleles 
associated with the GCC promoter haplotype and the Leu33 allele associated predominantly with 
the GAC promoter haplotype. There was some discrepancy in the occurrence of the less frequent 
haplotypes, which likely reflects ethnic heterogeneity in the present study. 
    We found a wide range in platelet αIIbβ3 expression which was not explained by ITGB3 promoter 
and Leu33Pro genotype or haplotype. Previous reports of the association of Leu33Pro with receptor 
density have been inconsistent [7]; however, the results of the present study lend further support for 
a lack of association of ITGB3 promoter polymorphisms and Leu33Pro with receptor density in 
unstimulated platelets. These results are inconsistent with the luciferase reporter gene results in 
which the common GCC and AAA promoter haplotypes were associated with a 50% increase in 
luciferase reporter gene expression compared with the GAC haplotype. The inﬂuence of the promoter 
polymorphisms on αv β3   expression in human endothelial cells or smooth muscle cells cannot be 
inferred from the results of our study regarding αIIbβ3 receptor expression due to cell specific 
regulation of αIIbβ3 and αv β3   receptor expression. Increased αIIbβ3 receptor expression is reported to 
arise from increased steady-state mRNA levels of both αIIb and β3 mRNA resulting from enhanced 
transcription [16]. In contrast, the expression of αv β3   appears to be largely dependent upon 
regulation of β3 expression, both at the transcriptional and post-transcriptional level [17, 18]. 
Therefore it cannot be excluded that the inﬂuence of the promoter polymorphisms on ITGB3 gene 
expression may have more of an influence on the ultimate expression of αv β3   than on the 
expression of αIIbβ3. 
       
       We found an association of ITGB3 -425A/C and Leu33Pro polymorphisms and the GCC-Pro33 
haplotype (hap3) with vWF activity. Since vWF is released from endothelial cell Weibel Palade bodies 
this may reﬂect an influence on endothelial cell function. Shear stress induces activation of 
endothelial cell αv β3   [19] and it has been shown that shear stress also induces increased secretion 
of vWF from endothelial cell Weibel Palade bodies [20]. Therefore it is possible that shear stress 
elicits differential responses in endothelial cells expressing different ITGB3 haplotypes. Studies of the 
Leu33Pro polymorphism indicated differential effects on platelet function, with the Pro33 allele 
associated with enhanced outside-in signaling in platelets and increased αgranule secretion [21]. In 
addition, enhanced cell migration on vitronectin and osteopontin was observed in CHO cells 
expressing αv β3   Pro33 [22], which may lend support for a functional effect of Leu33Pro in 
endothelial cells.
5. Conclusions  
Bioinformatics and reporter gene analyses suggested that the ITGB3 −468G/A, −425A/C and 
−400C/A polymorphisms may be functional. However, promoter haplotypes and promoter haplotypes 
in combination with the Leu33Pro polymorphism were not significantly associated with αIIbβ3 receptor 
density, despite wide inter-individual differences in receptor density. The GCC-Pro33 haplotype was, 
however, associated with enhanced vWF activity, which may indicate ITGB3 haplotype influences 
endothelial function. Further studies are required to determine whether ITGB3 haplotype is 
associated with enhanced αv β3   expression or activity.  
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Figures and Tables 
 
Fig.1.  
FootPrinter analysis of conserved motifs in the 5’
 
regions of the human, chimp, mouse and chicken 
ITGB3 genes. Five hundred base pairs of the 5’ region of the human, chimp, mouse and chicken 
ITGB3 genes underwent foot printing analysis to determine if there were any regions of conservation 
between the different species. (Panel A) Identical motifs detected in each species’ sequence have the 
same number. The phylogenetic tree on the right hand side shows the evolutionary relationship 
between the different species. (Panel B) Conserved motifs are underlined, several motifs between 




















Inﬂuence of the −468G/A, −425A/C and −400C/A polymorphisms in the 5
′ 
gene regulatory region of 
ITGB3 on ﬁreﬂy reporter gene expression in HEL and HMEC-1 cells. Fireﬂy luciferase values were 
normalized to Renilla luciferase activity and expressed relative to the wild type GAC construct. (Panel 
A) ﬁreﬂy/renilla luciferase values for HEL cells transiently transfected with each construct. ANOVA 
analysis, p = 0.02. (Panel B) ﬁreﬂy/renilla luciferase values for HMEC-1 cells transiently transfected 










Table 1  
 
 
Characteristics of study subjects  
 
                                                                          Subjects (n = 223)  
Age (years)                                                            42.3 (40.1–44.5) 
Male, n                                                                 112 (0.50) 
BMI (kg/m
2
)                                                           26.6 (5.63) 
Current smokers, n                                                 23 (0.10) 
 
Ethnicity  
  Caucasian, n                                                       131 (0.59)  
  African American, n                                               49 (0.22) 
  Mexican American, n                                             28 (0.13)  
  Asian, n                                                               13 (0.06)  
  Other, n                                                                 2 (0.01)  
Fibrinogen (gl−1)                                                       3.39 (1.35)  
vWF activity (%)                                                    110.6 (42.9)  
  
CABG, n                                                                  85 (0.38)  
Previous MI, n                                                         40 (0.18)  
Hypertension, n                                                       59 (0.27)  
Diabetes, n                                                              26 (0.12)  
Aspirina, n                                                               85 (0.38)  
 
Age presented as median (25th and 75th percentiles). Other variables presented as mean or 
geometric mean (S.D. or antilog S.D.) or number (frequency). CABG: coronary artery bypass graft. 
a  













Number of chromosomes 
(frequency)  





hapA: GAC  286 (0.64)  hap1: GAC-Leu33  279 (0.62)  
  hap7: GAC-Pro33     7 (0.02)  
hapB: AAA  69 (0.15)  hap2: AAA-Leu33    61 (0.13)  
  hap6: AAA-Pro33      8 (0.2)  
hapC: GCC  63 (0.14)  hap5: GCC-Leu33    20 (0.04)  
  hap3: GCC-Pro33    43 (0.10)  
hapD: AAC  22 (0.05)  hap4: AAC-Leu33    22 (0.05)  
           AAC-Pro33      0  
hapE: GAA  4 (0.01)  hap8: GAA-Leu33      3 (<0.01)  
  hap9: GAA-Pro33      1 (<0.01)  
hapF: ACC  2 (<0.01)  hap10: ACC-Leu33      1 (<0.01)  



















Table 3  
 
The relationship of ITGB3 polymorphisms with platelet αIIbβ3 receptor density, plasma ﬁbrinogen and 
plasma vWF activity  
 
                       -468G/A                      -425A/C                       -400C/A                                     Leu33Pro            
           Mean (95% CI)           p           Mean (95% CI)         p        Mean (95% CI)         p      Mean (95% CI)                  p 
αIIbβ3 (MFI) GG: 136 (133, 139)   0.12   AA: 136 (133, 139)   0.85   CC: 137 (134, 140)   0.62     LL: 137 (134, 140)            0.97  
            GA: 139 (134, 143)            AC: 138 (133, 143)             CA: 137 (132, 142)              LP: 136 (131,141) 
            AA: 126 (119, 133)            CC: 138 (131, 144)             AA: 128 (120, 137)               PP: 138 (133, 143)  
 
 
Fibrinogen (gL−1)GG: 3.36 (3.21,3.52) 0.62  AA: 3.36 (3.21,3.51) 0.33  CC: 3.40 (3.26,3.55) 0.92       LL: 3.35 (3.20, 3.50)      0.17  
                         GA: 3.51 (3.24,3.80)         AC: 3.60 (3.29,3.94)           CA: 3.43 (3.14,3.74)             LP: 3.68 (3.36, 4.02)  
                         AA: 3.40 (3.06,3.78)         CC: 3.35 (2.60,4.31)           AA: 3.58 (3.30,3.90)              PP: 3.32 (2.67, 4.12)  
 
vWF activity(%)GG: 112.7(105.1, 120.4)0.47 AA: 105.4(99.6, 111.2)0.01 CC: 113.1(106.0, 120.1)0.42 LL: 106.8(100.5, 113.2) 0.06 
                  GA: 108.3(99.3, 117.3)         AC: 124.4(110.0, 138.8)       CA: 105.3(95.2, 115.3)         LP: 121.8(109.6, 134.0)  
                  AA: 97.1(76.7, 117.5)           CC: 139.7(76.9, 202.5)         AA: 99.4(70.2, 128.7)           PP: 131.6(73.9, 189.3)  
 
 
Data presented as mean or geometric mean (95% conﬁdence intervals).  
MFI: mean ﬂuorescence intensity.  
 
 
 
 
 
 
 
 
 
 
 
